Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 3/20 | 0.56 |
| ▸ | CMA1 | P23946 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2308530 | 0.78 | LMNA (0.55) | DAOCMA1HTTMAPTKDM4E | |
| SCHEMBL8469096 | 0.74 | DAO (0.54) | DAOCMA1HTTMAPTKDM4E | |
| SCHEMBL3258886 | 0.73 | POLB (0.64) | DAOHTTMAPTALDH1A1TSHR | |
| SCHEMBL718459 | 0.73 | PTGS1 (0.58) | DAOCMA1HTTMAPTCA12 | |
| SCHEMBL18965894 | 0.72 | ALDH1A1 (0.51) | CMA1HTTMAPTKDM4EALDH1A1 | |
| SCHEMBL1861739 | 0.72 | CMA1 (0.65) | CMA1HTTMAPTKDM4EALDH1A1 | |
| SCHEMBL28554314 | 0.71 | DAO (0.49) | DAOHTTMAPTCA12POLB | |
| SCHEMBL1337353 | 0.71 | CA12 (0.57) | DAOHTTMAPTKDM4ECA12 | |
| SCHEMBL31267076 | 0.71 | DAO (0.49) | DAOCMA1HTTMAPTCA12 | |
| SCHEMBL11865299 | 0.71 | HDAC1 (0.59) | DAOHTTMAPTCA12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053214-B2 | β-sheet mimetics and composition and methods relating thereto | MYRIAD GENETICS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1651653-A1 | NOVEL CYANO THIAZOLIDES, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | Sanofi-Aventis Deutschland GmbH (DE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060084653-A1 | Beta-sheet mimetics and composition and methods relating thereto | MYRIAD GENETICS, INCORPORATED (US) | 2006-04-20 | — | — | US | disclosed |
| EP-1482941-A4 | BETA-SHEET MIMETICS AND COMPOSITION AND METHODS RELATING THERETO | MYRIAD GENETICS INC (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005012312-A1 | NOVEL CYANO THIAZOLIDES, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-02-10 | — | — | WO | disclosed |
| EP-1482941-A1 | BETA-SHEET MIMETICS AND COMPOSITION AND METHODS RELATING THERETO | Myriad Pharmaceuticals, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040014763-A1 | beta-sheet mimetics and composition and methods relating thereto | MYRIAD PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | US | disclosed |
| US-20040014763-A1 | beta-sheet mimetics and composition and methods relating thereto | MYRIAD PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | US | disclosed |
| US-20040014763-A1 | beta-sheet mimetics and composition and methods relating thereto | MYRIAD PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | US | disclosed |
| WO-2003068237-A1 | BETA-SHEET MIMETICS AND COMPOSITION AND METHODS RELATING THERETO | MYRIAD GENETICS, INC. (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014763-A1 | beta-sheet mimetics and composition and methods relating thereto | TPSAB1, TPSB2, TPSD1 | DAO 134/4885CMA1 5/4885HTT 1307/4885 |
| US-20060084653-A1 | Beta-sheet mimetics and composition and methods relating thereto | TPSAB1, TPSB2, TPSD1 | DAO 174/4885CMA1 4/4885HTT 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.